Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT02243579 Completed - Clinical trials for Recurrent Mycosis Fungoides and Sezary Syndrome

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Start date: October 15, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IVB mycosis fungoides or Sezary syndrome that has returned after a period of improvement or has not responded to at least one type of treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells.

NCT ID: NCT02243332 Completed - Clinical trials for Patellofemoral Pain Syndrome

Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain

Start date: September 2014
Phase: N/A
Study type: Interventional

The purpose of this small, pilot study is to evaluate a novel device that uses neuromuscular electrical stimulation to assist quadriceps muscles as a user walks. This study will involve use of this device on individuals with patellofemoral pain, a relatively common injury among active people, to see if quadriceps stimulation could mitigate disparities in quadriceps activation timing that may indirectly lead to knee pain.

NCT ID: NCT02243124 Terminated - Clinical trials for Myelodysplastic Syndromes

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The purpose of the study is to test the safety of six cycles of cenersen treatment and to begin to test the hypothesis that intermittent administration of cenersen may lead to a reduced dependence on transfusion.

NCT ID: NCT02242656 Withdrawn - Clinical trials for Short Bowel Syndrome

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

Start date: December 2014
Phase: Phase 3
Study type: Interventional

MP-101 will be evaluated in this study to see if it is safe, tolerable, and can help people with Short Bowel Syndrome. This study will also find out if taking MP-101 can improve the symptoms of Short Bowel Syndrome and reduce the number of times subjects experience bowel movements.

NCT ID: NCT02242175 Recruiting - Clinical trials for Irritable Bowel Syndrome

Efficacy of Hydrogen Breath Test in the Patients With Irritable Bowel Syndrome

Start date: September 2014
Phase: N/A
Study type: Interventional

Irritable bowel syndrome is characterized by abdominal discomfort and bowel habit change. It is increasing worldwide. But the pathophysiology of the irritable bowel syndrome is not proven. So, the treatment's target is the relief of the symptoms. Small intestinal bacterial overgrowth considered as the cause of the irritable bowel syndrome. Because, it is related to the postprandial abdominal discomfort and the abdominal discomfort could be relieved after taking antibiotics. There are several diagnostic methods for small intestinal bacterial overgrowth. hydrogen breath test is non-invasive method for diagnosis of the small intestinal bacterial overgrowth. But, there is no standardized cut-off value for the hydrogen breath test. So, we want to compare the hydrogen breath test between the irritable bowel syndrome patients and normal people. And then, we want to analyze the efficacy of hydrogen breath test for the diagnosis of irritable bowel syndrome.

NCT ID: NCT02241954 Completed - Clinical trials for Thoracic Insufficiency Syndrome (TIS)

Vertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome

VEPTR
Start date: November 11, 2010
Phase:
Study type: Observational

The hypothesis of the study is that individuals with poor pulmonary function secondary to TIS will benefit from expansion thoracoplasty. The investigators specific aims are to: 1. Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation 2. Offer expansion thoracoplasty therapy to TIS patients with 1. poor pulmonary function at enrollment 2. progressive decline in pulmonary function 3. progressive chest wall and/or spinal deformity 4. lack of appropriate increase in thoracic volume during growth 3. Document efficacy of expansion thoracoplasty for TIS patients

NCT ID: NCT02241148 Terminated - Clinical trials for Patellofemoral Pain Syndrome

Close Kinetic Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome

Start date: February 2014
Phase: N/A
Study type: Interventional

The investigators will include patients attending outpatient clinic in the area of Orthopedics and Traumatology of our hospital with a diagnosis of unilateral Patellofemoral Pain Syndrome. Two groups would be made, the control group will receive treatment with acetaminophen and physical therapy rehabilitation, closed chain exercises and stretches at home intended for the strengthening of quadriceps, abductors and internal rotators of the hip for the duration of six weeks. The experimental treatment group will receive the above plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping on the affected knee. Both groups will be evaluated by an external consultation. They will be assessed by the Tegner Activity Scale, the Kujala score of the WOMAC and visual analog scale (VAS) for pain assessment; these scales will be applied at the beginning, third and sixth week

NCT ID: NCT02240914 Recruiting - Clinical trials for May-Thurner Syndrome

Vascular Ultrasound Versus Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction

USG-DIVO
Start date: February 2013
Phase: N/A
Study type: Observational [Patient Registry]

- Determine the sensitivity, specificity and accuracy of vascular ultrasound, using direct and indirect ultrasonographic signs, in the obstructive diseases of iliac venous segment, in patients with advanced chronic venous insufficiency (CEAP 3-6), considering the intravascular ultrasound (IVUS) as the gold standard for this diagnosis. - Develop an algorithm for noninvasive ultrasound investigation of obstructive lesions in the iliac segment in patients with advanced chronic venous insufficiency (CEAP 3-6).

NCT ID: NCT02240888 Completed - Scleroderma Clinical Trials

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

Vaccimil
Start date: October 2011
Phase: N/A
Study type: Interventional

The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on immune response elicited by pneumococcal vaccination using 13-valent conjugate vaccine and influenza vaccination. In addition, the aim is to study the clinical aspects of vaccination regarding: tolerability in immunosuppressed patients with IRD, impact on existing rheumatic disease, possible association with onset of new autoimmune diseases, long-term immunity following pneumococcal vaccination, efficacy in preventing invasive pneumococcal diseases and influenza related serious infections. Results from this study are expected to bridge the existing knowledge gap and contribute to body of evidence needed for recommendations and implementation of vaccination program in IRD patients.

NCT ID: NCT02240706 Terminated - Clinical trials for Myelodysplastic Syndromes

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Start date: January 22, 2015
Phase: Phase 2
Study type: Interventional

Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) with symptomatic anemia. Phase II: To investigate safety and efficacy of BI 836858 plus Best Supportive Care compared to Best Supportive Care alone in low or intermediate-1 risk MDS patients with symptomatic anemia.